LAUSR

Disorders of iron metabolism (DIM) and accompanying anemia afflict many patients with advanced heart failure with reduced ejection fraction (HFrEF) who are candidates for continuous-flow left ventricular assist device (CF-LVAD) support.1 Hemolysis, bleeding, and inflammation contribute to DIM in the presence of CF-LVAD therapy, causing a milieu that is distinct from patients with advanced HFrEF without a CF-LVAD.1,2 Efficacy of intravenous (IV) must also be balanced against the increased risk of infection from the administration of the iron product in a immunocompromised CF-LVAD population.3,4 In this exploratory investigation, we sought to assess the effect of IV iron administration on iron and anemia indices in patients implanted with CF-LVADs and to compare their response with a similar cohort of advanced HFrEF patients without CF-LVADs.